• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Mason Heather L

    3/18/26 7:20:54 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMTX alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Mason Heather L

    (Last)(First)(Middle)
    PAUL-EHRLICH-STR. 15

    (Street)
    TUBINGEN72076

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Immatics N.V. [ IMTX ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy) (1)06/30/2030Ordinary Shares25,000$10D
    Stock Option (Right to Buy) (1)12/08/2031Ordinary Shares15,000$11D
    Stock Option (Right to Buy) (1)06/13/2032Ordinary Shares25,000$7.94D
    Stock Option (Right to Buy) (1)06/26/2033Ordinary Shares25,000$11.41D
    Stock Option (Right to Buy) (1)06/24/2034Ordinary Shares40,000$12D
    Stock Option (Right to Buy) (2)06/23/2035Ordinary Shares41,500$5.44D
    Explanation of Responses:
    1. These options to purchase ordinary shares of the Issuer (each such option, an "Option") are fully vested.
    2. These Options vest 100% on the first anniversary of the grant date, June 24, 2025.
    Remarks:
    Exhibit List - Exhibit 24.1 - Power of Attorney
    /s/ Edward Sturchio, attorney-in-fact for Heather L. Mason03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $IMTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMTX

    DatePrice TargetRatingAnalyst
    4/28/2026Buy
    TD Cowen
    3/16/2026Buy
    Jefferies
    9/18/2025$16.00Buy
    Guggenheim
    5/28/2025$10.00Buy
    Deutsche Bank
    10/7/2024$19.00Overweight
    Piper Sandler
    11/2/2023Overweight
    Cantor Fitzgerald
    3/31/2023$12.00Buy
    Mizuho
    3/24/2023$16.00Buy
    Bryan Garnier
    More analyst ratings

    $IMTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

    One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanomaAnzu-cel showed a 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progressionFindings reinforce the continued effectiveness of anzu-cel to treat advanced

    6/1/26 8:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer

    IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancerIn head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously

    5/31/26 9:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

    One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 monthsAdditional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 yearsIMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populationsClinical anti-tumor activity observed

    5/30/26 8:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    SEC Filings

    View All

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    6/2/26 8:01:07 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Immatics N.V.

    6-K - Immatics N.V. (0001809196) (Filer)

    6/1/26 8:02:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Immatics N.V.

    SCHEDULE 13G - Immatics N.V. (0001809196) (Subject)

    5/15/26 1:46:05 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Immatics N.V.

    TD Cowen initiated coverage of Immatics N.V. with a rating of Buy

    4/28/26 7:45:07 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Immatics N.V.

    Jefferies resumed coverage of Immatics N.V. with a rating of Buy

    3/16/26 9:36:08 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Immatics N.V. with a new price target

    Guggenheim initiated coverage of Immatics N.V. with a rating of Buy and set a new price target of $16.00

    9/18/25 8:43:36 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Reinhardt Carsten Alexander Johannes

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:41:57 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Britten Cedrik Michael

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:39:50 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Sturchio Edward A Jr

    3 - Immatics N.V. (0001809196) (Issuer)

    3/18/26 7:39:40 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Leadership Updates

    Live Leadership Updates

    View All

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

    Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur in 2026 Anzu-cel (IMA203) PRAME Cell Therapy: One-time infusion continues to show strong clinical benefit and favorable tolerability in 16 patients with metastatic uveal melanoma in latest update on Phase 1b data presented at the ESMO 2025 Presidential Symposium: cORR of 67%, mDOR of 11.0 months, mPFS of 8.5 months and mOS not reached at 14.3 months mFUIMA203CD8 PRAME Cell Therapy (GEN2): Phase 1a clinical trial ongoing with next data update, including dose escalation data in ovarian cancer

    11/17/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Amie Krause as Chief People Officer

    Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Amie Krause as Chief People Officer ("CPO") effective October 27, 2025. Ms. Krause brings more than 20 years of experience in shaping culture, leading organizational growth and aligning talent with business strategy, including across global biopharmaceutical companies. In this newly established role, she will lead Immatics' human resources, focusing on organizational development and operations as the company transitions to commercial stage."As we

    10/27/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Appoints Venkat Ramanan as Chief Financial Officer

    Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company")), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, today announced the appointment of Venkat Ramanan, Ph.D., as Chief Financial Officer ("CFO"), effective immediately. Dr. Ramanan is a seasoned financial leader in the biopharmaceutical industry with over 25 years of experience at companies including Seagen, Gilead Sciences and Amgen. He brings deep financial expertise in facilitating successful product launches, establishing scalable operations in global markets and enabling corporate transactions. He joins Immatics from Anthos The

    10/1/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Financials

    Live finance-specific insights

    View All

    Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

    Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME Bispecific at RP2D range resulted in a 30% cORR (6/20) across all indications, including 29% (4/14) in melanoma and 2/3 confirmed responses in ovarian carcinoma IMA401 MAGEA4/8 Bispecific at ≥1 mg resulted in a 25% cORR (2/8) in head and neck cancer, 29% cORR (2/7) in melanoma and promising clinical activity in sqNSCLC Phase 1a dose escalation completed for both trials; data support IMA402 PRAME Bispecific dev

    11/12/25 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

    Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST Company announces updated Phase 1b clinical data on ACTengine® IMA203 targeting PRAME in 28 heavily pretreated metastatic melanoma patients with substantially enhanced maturity compared to the last data update in May 2024 and provides the first report on progression-free survival (PFS) and overall survival (OS)Based on the Phase 1b data, the Company will proceed directly to a registration-enabling Phase 3 trial Regulatory pathway and clinical trial design for IMA203 finalized following FDA Type D meetings and meeting with the Paul Ehrlich Institute (PEI); RP2D and CMC package confirmedIMA203 conti

    10/10/24 6:30:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

    Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET IMA203 data with focus on melanoma patients presented at the International Congress of the Society for Melanoma Research today, November 8 IMA203 GEN1 TCR cell therapy targeting PRAME – update on Phase 1a and Cohort A Continues to be well tolerated50% confirmed objective response rate (cORR) in melanoma patients treated at recommended Phase 2 dose; durability with some ongoing responses at >15 months and median duration of response not reached at a median follow-up of 14.4 monthsTargeted to enter registration-enabling Phase 2 trial in melanoma in 2024; discussions with FDA ongoing based on recently ob

    11/8/23 7:00:00 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 1:28:33 PM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Immatics N.V.

    SC 13G - Immatics N.V. (0001809196) (Subject)

    11/14/24 6:32:45 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Immatics N.V.

    SC 13G/A - Immatics N.V. (0001809196) (Subject)

    11/8/24 10:46:38 AM ET
    $IMTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care